BioSpace News Archive

NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in the Cowen 43rd Annual Health Care Conference as part of the Novel Oncology Targets Panel and will provide a business update focusing on NGM Bio’s wholly-owned oncology portfolio on Tuesday, March 7th, at 9:10 am ET.

Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that European Patent Office (EPO) has issued a notice of intention to grant for its patent application titled, “Administration of Serine Protease Inhibitors to the Stomach.”

UC San Francisco (UCSF) is conducting a six-month clinical trial on hypertrophic cardiomyopathy (HCM) using Vivalink’s Biometrics Data Platform.

Marengo Therapeutics, Inc., a company pioneering novel immuno-therapeutics targeting the T cell receptor (TCR) Vβ to selectively activate the right T cell subsets to fight cancer, today announced the appointment of Kevin Chin, M.D., M.S., as Chief Medical Officer.

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced a new partnership with QIAGEN N.V. (NYSE: QGEN) that will pair QIAseq reagent technology with the SOPHiA DDM™ platform to enhance tumor analysis through next-generation sequencing (NGS).

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report fourth quarter and year-end 2022 financial results on Wednesday, March 8, 2023.

Pharma-Bio Serv, Inc., a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, announced that the Board of Directors approved a Special Dividend of $0.075 per share for shareholders.

Dr. John Patton is recognized as a Leader in the Inhaled Formulation Solutions To Bring Industry Expertise To Innovative, Research-Based Pharmaceutical Firm

Britannia Life Sciences Inc. (CSE: BLAB) (FSE: L020) (“Britannia” or the “Company”) is pleased to provide its unaudited financial results for the three- and nine-month periods ended December 31, 2022.

Hamamatsu Photonics announces the release of a new high-speed kinetic plate imager, the FDSS-GX, ideal for kinetic cell-based assay development, including GPCR / ion channel research and screening for drug discovery.